ArticleDigestive diseases (Basel, Switzerland)2025
Comparable Long-Term Liver Transplant Outcomes in Primary Sclerosing Cholangitis with and without MASLD: Last Decade Analysis of the UNOS Database.
Article in Digestive diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of liver transplants (LT) in the USA. Despite its overlap with other indications, its intersection with primary sclerosing cholangitis (PSC) remains unexplored.
methodsWe performed a retrospective cohort study using the UNOS/OPTN database (2013-2024) to evaluate outcomes in PSC, MASLD, and PSC/MASLD. Exclusions included prior/multi-organ transplants, body mass index (BMI) <15 kg/m2, pediatric recipients, and other liver diseases. A propensity-matched analysis adjusting for age and sex was conducted. Outcomes included LT probability, waitlist survival, and post-LT graft and patient survival, assessed by Kaplan-Meier and Cox proportional hazards models.
resultsWe included 255 PSC, 255 MASLD, and 85 PSC/MASLD patients, matched 1:3:3. BMI and diabetes rates were highest in PSC/MASLD (31.2 kg/m2; 43.5%) and MASLD (30.9 kg/m2; 54.5%) (p < 0.001). Hepatic decompensation, including ascites and encephalopathy, was more common in PSC/MASLD and MASLD than PSC (p < 0.001). On the waitlist, PSC/MASLD had the best 1-year survival (93%) but declined sharply to 70% by 4 years (95%), compared to PSC (77%) and MASLD (63%) (p = 0.02). PSC/MASLD also had the highest 5-year LT probability (52%), followed by MASLD (46%) (p < 0.001). Post-LT, patient and graft survival were similar across groups. In multivariate analysis, diabetes (HR 1.22) and life support (HR 1.39) independently predicted worse post-LT outcomes.
conclusionsPSC/MASLD had a higher transplant probability and lower waitlist survival than PSC. Posttransplant outcomes were similar across groups. Diabetes and life support independently worsened post-LT outcomes, emphasizing the need for diabetes management in MASLD and PSC/MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.